What is Extended-Spectrum Beta-Lactamase (ESBL)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 12, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

What is Extended-Spectrum Beta-Lactamase (ESBL)?

ESBL refers to a group of plasmid-mediated enzymes produced by certain gram-negative bacteria that hydrolyze (break down) extended-spectrum cephalosporins, aztreonam, and penicillins, but remain inhibited by clavulanic acid and susceptible to carbapenems. 1

Mechanism and Enzyme Types

  • ESBLs are enzymes that confer resistance by hydrolyzing the beta-lactam ring of antibiotics, rendering them ineffective 2, 3
  • The most common ESBL types derive from TEM, SHV, and CTX-M enzyme families, with additional groups including KPC, AmpC, and certain OXA variants 1, 4
  • These enzymes are typically encoded on plasmids, which allows for easy horizontal transfer between bacteria and often carry co-resistance genes for other antibiotic classes 2, 3

Common Organisms

  • Klebsiella pneumoniae, Klebsiella oxytoca, and Escherichia coli are the most common ESBL-producing organisms 1
  • Other Enterobacteriaceae including Proteus mirabilis, Enterobacter species, and Citrobacter species can also produce ESBLs 1

Resistance Profile

ESBL-producing bacteria are resistant to all penicillins, all cephalosporins (including third-generation cephalosporins like ceftriaxone, cefotaxime, ceftazidime, and fourth-generation cefepime), and aztreonam, but remain susceptible to carbapenems. 1

  • Co-resistance to aminoglycosides (gentamicin, tobramycin), trimethoprim-sulfamethoxazole, and fluoroquinolones is frequently observed, severely limiting treatment options 1
  • When ESBL producers also express AmpC beta-lactamases, they gain additional resistance to cephamycins, but carbapenems remain effective 1

Laboratory Detection

  • ESBL-producing organisms are identified through antimicrobial susceptibility testing showing specific resistance patterns to beta-lactam antibiotics 5
  • The Clinical and Laboratory Standards Institute (CLSI) states that routine ESBL testing is no longer necessary before reporting results when using newer interpretive criteria for cephalosporins 5
  • Common to all ESBL detection methods is the principle that the activity of extended-spectrum cephalosporins against ESBL-producing organisms will be enhanced by the presence of clavulanic acid 2, 3
  • MIC (Minimum Inhibitory Concentration) determination is another laboratory method used for ESBL detection 5

Important Caveat

  • The new ceftazidime and cefepime susceptible breakpoints fail to identify many ESBL-producing E. coli, K. pneumoniae, and K. oxytoca, which can lead to inappropriate antibiotic selection 5

Clinical Significance

  • Identification of ESBL-producing organisms is critical for appropriate antibiotic selection, as these infections are associated with higher mortality, complications, and prolonged hospitalization if not properly treated 6
  • Carbapenems (imipenem, meropenem, ertapenem) are the treatment of choice for serious infections caused by ESBL-producing organisms 1, 5
  • For uncomplicated infections, alternative treatments include fosfomycin, nitrofurantoin, and aminoglycosides, depending on susceptibility and infection type 1
  • Newer agents such as ceftazidime-avibactam have activity against ESBL-producing organisms and may be valuable for treating infections to preserve carbapenems 1, 7

References

Guideline

ESBL Infections: Risk Factors and Treatment Approaches

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Extended-spectrum β-lactamases in Gram Negative Bacteria.

Journal of global infectious diseases, 2010

Research

Extended-spectrum beta-lactamases: a clinical update.

Clinical microbiology reviews, 2005

Research

Defining an extended-spectrum beta-lactamase.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2008

Guideline

Identifying Extended-Spectrum Beta-Lactamase (ESBL) Producing Organisms

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Diagnosing Extended-Spectrum Beta-Lactamase (ESBL) Infections

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.